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A Ab bs st tr ra ac ct t
DNA copy number variations (CNVs) are an important component of genetic variation, affecting
a greater fraction of the genome than single nucleotide polymorphisms (SNPs). The advent of
high-resolution SNP arrays has made it possible to identify CNVs. Characterization of widespread
constitutional (germline) CNVs has provided insight into their role in susceptibility to a wide
spectrum of diseases, and somatic CNVs can be used to identify regions of the genome involved
in disease phenotypes. The role of CNVs as risk factors for cancer is currently underappreciated.
However, the genomic instability and structural dynamism that characterize cancer cells would
seem to make this form of genetic variation particularly intriguing to study in cancer. Here, we
provide a detailed overview of the current understanding of the CNVs that arise in the human
genome and explore the emerging literature that reveals associations of both constitutional and
somatic CNVs with a wide variety of human cancers.
Published: 16 June 2009
Genome Medicine 2009, 1 1: :62 (doi:10.1186/gm62)
The electronic version of this article is the complete one and can be
found online at http://genomemedicine.com/content/1/6/62
© 2009 BioMed Central Ltd 
C Co op py y   n nu um mb be er r   v va ar ri ia at ti io on ns s: :   d dy yn na am mi ic c   g ge en no om me es s
Our genomes are not the stable places we once thought they
were. Recent genome-wide studies have shed light on copy
number variations (CNVs), an unexpectedly frequent, dynamic
and complex form of genetic diversity, and have quickly
overturned the idea of a single diploid human ‘reference
genome’. Although the characterization of the extent and
location of these regions in healthy genomes is far from com-
plete, many groups, including ours, are actively trying to
determine the clinical impact of CNVs in patient populations.
CNVs are structurally variant regions in which copy number
differences have been observed between two or more
genomes [1]. Defined as being larger than 1 kilobase (kb) in
size, CNVs can involve gains or losses of genomic DNA that
are either microscopic or submicroscopic and are, therefore,
not necessarily visible by standard G-banding karyotyping.
Until recently, only a few copy-number-variable loci had
been identified, such as duplications at the α7-nicotinic
receptor gene (CHRNA7) at 15q13-15 [2] and variation at the
major histocompatibility complex locus [3]. In 2004, signifi-
cant advances in DNA array technology enabled the dis-
covery of many CNVs, revealing a novel and pervasive form
of inter-individual genomic variation [4,5]. These pioneering
genome-scale efforts used two different platforms to find 76
CNVs in 20 individuals [5] and 255 CNVs in 55 individuals
[4], some of which were common to both studies, suggesting
possible hotspot regions of CNVs in the human genome.
Even this was soon found to be an under-representation of
the number of CNVs; follow-up studies have since ascer-
tained many thousands of CNV regions in hundreds of
healthy individuals. In fact, the recent increase in scientific
interest in CNVs, combined with improvements in micro-
array fabrication (higher density at lower cost) and the
development of new informatics techniques, have led to the
ascertainment of approximately 21,000 CNVs, or around
6,500 unique CNV loci, in the five short years since this form
of genetic variation was first revealed (these figures comefrom the March 2009 update of the Database of Genomic
Variants (DGV) [4]). CNVs are now thought to cover at least
10% of the human genome. Furthermore, next-generation
sequencing technologies will soon be used to sequence
thousands of genomes along with their CNVs.
C CN NV Vs s   a an nd d   d di is se ea as se e: :   m mu ut ta ab bl le e   g ge en no om me es s
The CNV map for the human genome is being continuously
refined and has already pinpointed the location, copy number,
gene content, frequency and approximate breakpoints of
numerous CNVs in the healthy population. These structural
variants can alter transcription of genes by altering dosage
or by disrupting proximal or distant regulatory regions, as
has been shown globally in the healthy human [6], mouse [7]
and rat genomes [8]. It is, however, the specific disease-
associated CNV loci that have been particularly scrutinized
and that therefore provide the most detailed examples of how
CNVs can alter cellular function. We will highlight three
insights in particular from the literature: that pathogenic CNVs
often contain multiple genes, that the effect of a pathogenic
CNV is not limited to the gene(s) it contains, and that
pathogenic CNVs can have reciprocal deletions/duplications.
T Th he e   n nu um mb be er r   o of f   g ge en ne es s   i in n   p pa at th ho og ge en ni ic c   C CN NV Vs s
Genomic rearrangements give rise to a variety of diseases
classified as ‘genomic disorders’ [9]. Because they involve
large regions, it is common for genomic disorders to include
many deleted or duplicated genes, unlike traditional
mutations that affect a single coding-region change of one
gene. These genes can be either fully encompassed or partially
overlapped by the pathogenic CNV. Deletions of 22q11.2 are
associated with DiGeorge/velocardiofacial syndrome and
include the catechol-O-methyltransferase gene, the T box
transcription factor 1 gene and others [10]. Similarly, the
autosomal dominant Prader-Willi syndrome (15q11-q13
deletion) involves many genes [11], and the Williams-Beuren
syndrome (7q11.23 deletion) involves 28 genes [12]. As
microarray resolution increases, genomic disorders will
certainly be found that are caused by small CNVs involving
only a single gene, or even a portion of one gene.
T Th he e   s so ou ur rc ce e   o of f   t th he e   e ef ff fe ec ct t   o of f   a a   p pa at th ho og ge en ni ic c   C CN NV V
Usually, the genes contained in the pathogenic CNV are
candidates for association with the clinical phenotype under
study. However, research on genomic disorders has shown
that some genes within a CNV may not be necessary, or may
not be sufficient, to cause the observed disease. For example,
a recurrent 3.7 Mb microdeletion is responsible for 70% of
cases of Smith-Magenis syndrome (SMS) [13], a neuro-
behavioral disorder involving sleep disturbance, craniofacial
and skeletal anomalies, intellectual disability and distinctive
behavioral traits. Although the size of the deletions observed
varies, the identification of a common ‘critical region’
(1.5 Mb) in SMS patients led to the conclusion that the
retinoic acid induced 1 (RAI1) gene alone is responsible for
most SMS features. Indeed, RAI1 point mutations have been
seen in patients without deletions with similar phenotypes,
thus confirming that this gene (of the 13 in the critical
region) is necessary to cause SMS. Patients with additional
genes deleted have a variable and more severe phenotype. In
contrast, in Williams-Beuren syndrome, not only the
aneuploid genes but also genes far outside the deleted region
have reduced expression and are thought to contribute to the
phenotype [14]. Such long-range influence of CNVs on
distant gene expression is proposed to be caused by
positional effects [15].
R Re ec ci ip pr ro oc ca al l   d de el le et ti io on ns s   a an nd d   d du up pl li ic ca at ti io on ns s
Recombination between highly homologous sequences (non-
allelic homologous recombination) can generate deletions,
duplications, inversions and translocations. The sequence
architecture that allows one copy number change can also
allow its reciprocal at the same locus. The reciprocal events
usually cause different phenotypes and occur at different
frequencies in the population and at different rates during
meiosis [16].
C CN NV Vs s   a an nd d   c ca an nc ce er r   p pr re ed di is sp po os si it ti io on n: :   f fi ir rs st t   h hi it ts s   t to o   t th he e
t tu um mo or r   g ge en no om me e
The goal of cancer genetics is to discover all variant alleles
that predispose to neoplasms. To this end, single nucleotide
polymorphisms (SNPs) have been the most widely studied
form of genetic variation and, by using massive whole-
genome studies (genome-wide association (GWA) studies),
many common SNPs have been shown to be associated with
cancer and other complex traits. However, the results of
these efforts have not explained much of the heritability of
disease [17]. This is perhaps because GWA studies have
mostly ignored the inter-individual genetic variation
provided by CNVs, which affect more than 10% of the human
genome. CNVs, especially smaller variants, have been
essentially hidden from view until recently; thus, only a
handful of studies have found an association of CNVs with
cancer. Once these CNVs have been identified, one can only
assume that CNVs will explain a larger portion of the genetic
basis of cancer. Once identified, common and rare CNVs
should be considered separately, as they may have very
different roles in cancer.
C Co om mm mo on n   c ca an nc ce er r   C CN NV Vs s
As with SNPs, CNVs that are found frequently in the healthy
population (common CNVs) are very likely to have a role in
cancer etiology. In the only study published so far that
begins to test the hypothesis that common CNVs are
associated with malignancy, we [18] created a map of every
known CNV whose locus coincides with that of bona fide
cancer-related genes (as catalogued by [19]); we called these
cancer CNVs. In an initial analysis [18], we examined 770
healthy genomes using the Affymetrix 500K array set, which
has an average inter-probe distance of 5.8 kb. As CNVs are
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surprising to find 49 cancer genes that were directly
encompassed or overlapped by a CNV in more than one
person in a large reference population (Figure 1). In the top
ten genes, cancer CNVs could be found in four or more
people. In this analysis only CNVs directly overlapping a
cancer gene were selected (either both breakpoints were
inside the genomic interval containing the gene, both were
outside the interval, or one breakpoint was inside while the
other was outside). However, this is probably an under-
estimate of the actual number of common cancer CNVs, for
two reasons. First, many smaller variants are missed at the
resolution of this array: the mean size of CNVs found using
the Affymetrix 500K array is 206 kb [20], whereas the CNVs
found using the newer Affymetrix 6.0 platform with a
median inter-marker distance of less than 700 bp are 5-15
times smaller [21]. Second, as discussed above, there are
unquestionably additional, more distal CNVs that have a
long-range effect on cancer gene transcription levels.
Validating the initial observation [18], many of these genes
are also found in the DGV, a curated list of CNVs compiled
from numerous publications [4]. Analysis of the DGV [22]
shows that nearly 40% of cancer-related genes are inter-
rupted by a CNV. This trend continues: even among the ten
most recent CNV publications in the DGV (those published
after February 2008), many important tumor suppressor
genes and oncogenes can be found with diverse functions,
including apoptosis, control of cell cycle checkpoints and
DNA repair, and numerous translocation and fusion gene
partners. An example of this is Rad51L1, a gene that is a
member of the RAD51 family; this is essential for DNA
repair by homologous recombination and has been shown by
a GWA study to contain a SNP that is strongly associated
with breast cancer [23].
The challenge will be to determine which of these genes are
dosage-sensitive and which tissues containing these
common cancer CNVs will be susceptible to malignant trans-
formation and growth. One approach is to characterize
specific cancer CNVs in great detail, in terms of both popu-
lation frequency and breakpoint sequence [24]. For
example, in a pilot candidate-gene association study, we
found a cancer CNV at the gene MLLT4 (a  Ras target
encoding a protein that regulates cell-cell adhesion) that
seems to be associated with the Li-Fraumeni cancer
predisposition disorder (LFS); individuals affected with LFS
harbor a germline heterozygous mutation of the Tp53 tumor
suppressor gene [18]. The frequency of this CNV is
significantly increased in LFS (P = 0.006, Fisher’s exact
test): 3 of the 19 LFS probands (15.8%; observed/expected =
3/0.4 = 7.5) harbored the CNV duplication, whereas only 12
of 710 healthy individuals from the reference population
(1.69%; observed/expected = 12/14.6 = 0.82) harbored the
CNV.
A nice illustration of a focal CNV with phenotypic effect is
given by the mitochondrial tumor suppressor gene (Mtus1);
Frank  et al. [25] found that a small deletion in Mtus1 is
associated with a decreased risk of familial and high-risk
breast cancer. Using long-range PCR, we independently fine-
mapped this common cancer CNV and genotyped it in a
panel of healthy controls. Although it is only 1.1 kb in size,
the deletion removes an entire exon of Mtus1. Direct
sequencing reveals a 41 bp stretch of homology flanking the
exon, which leads to this deletion by non-allelic homologous
recombination (Figure 2).
These examples demonstrate hypothesis-driven approaches,
which are restricted to genes for which there is an a priori
association with cancer. Ultimately, it will be important to be
able to discover and test every CNV in a genome for cancer
susceptibility, but although this hypothesis-free approach is
becoming technically tractable and more economical, such
studies do have unique analytical challenges. As elaborated
upon elsewhere [26,27] these challenges include: the un-
known allele frequency and integer copy number of most
CNVs, both within and among populations; the absence of
sequence-level breakpoint information for most CNVs and
the architectural complexity of some CNV regions, including
smaller CNVs within larger ones [24].
R Ra ar re e   c ca an nc ce er r   C CN NV Vs s
Common cancer SNPs - and by analogy common cancer
CNVs - each confer only a minor increase in disease risk, but
collectively they may cause a substantially elevated risk. In
contrast, the mutations associated with hereditary cancer
syndromes are frequently highly penetrant on their own and
are usually inherited in an autosomal dominant manner.
Unlike low-penetrance alleles, rare high-penetrance muta-
tions will almost always co-segregate with the disease in
families.
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F Fi ig gu ur re e   1 1
Distribution of common cancer CNVs in the human genome. The
chromosomes containing common cancer CNVs in the human genome
are shown, with centromeric regions in red (using data from [19]) and
Giemsa banding patterns in white, grey or black. Loci are in green if they
were found to contain a cancer-related gene that is overlapped or

















19There are over 200 cancer syndromes and although most
arise infrequently, they account for 5-10% of all cancer cases
[28]. These are caused by base-pair-sized germline muta-
tions in many central tumor suppressor genes - such as
TP53, APC, BRCA1, BRCA2, PTEN, and RB1 - and (fewer)
oncogenes, including HRAS and RET.
The role of large structural mutations in cancer syndromes
has been less appreciated, probably because genomic
deletions or duplications are not readily detected by PCR-
based sequencing. New multiplexing methods, especially
multiplex ligation-dependent probe amplification (MLPA)
[29], allow targeted copy number assessment of single gene
or exon changes. This has led to a recent upsurge in
discoveries of patients and families with rare pathogenic
CNVs that strongly predispose to cancer. Of the 70 germline
cancer genes in the Cancer Genes Census [30], 28 have been
reported to be mutated by genomic deletion or duplication
(the genes and citations are shown in Table 1). We hypothesize
that many of the remaining gene mutations will be found to
have a genomic equivalent and, perhaps more importantly,
that predisposing CNVs will be found in other regions not
usually associated with hereditary cancer. A recent report by
Jackson  et al. [31] describing five patients with rhabdoid
predisposition syndrome and deletions at SMARCB1
(22q11.2) highlights the benefits of a global approach to CNV
detection: using SNP arrays to gain a broad perspective on
the  SMARCB1  deletion and surrounding chromosomal
landscape, it was found that the extent of two patients’
deletions in fact extended past SMARCB1, impinging on
neighboring genes, and explaining their clinical phenotype.
The presence of rare cancer CNVs leads to many questions:
do they differ from base-pair changes at the same locus?
What is their penetrance? What are the mutational
processes that give rise to them? Do they have reciprocal
deletions/duplications? Do they have long-range effects on
gene expression? These questions provide fertile ground for
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F Fi ig gu ur re e   2 2
Cancer CNV breakpoint mapping. We mapped a 1.1 kb deletion in the mitochondrial tumor suppressor gene, MTUS1, to base-pair resolution. The
affected portion of the gene is shown, including an exon (blue) that is deleted in the presence of the CNV. Two 41 bp repeats (with sequence
AAATAAGAACCAAGTCCAAATACATCTTTGGAATGAAAGAG) were found at the breakpoints (red), while the sequence of the junction fragment is
shown in the chromatogram.
Scale
Chr 8: 17,624,500 17,625,000 17,625,500 17,626,000
1kb
MTUS1future research. These studies may involve identifying novel
CNVs in unexplained familial clusterings of cancer, or the
use of in vitro models in which cancer CNVs are created to
measure their effect on cellular proliferation, genomic
instability and the other hallmarks of cancer [32].
One potential model to explain the contribution of common
and rare CNVs to cancer predisposition is shown in Figure 3.
We propose that the number of copy-number-variable
regions in healthy persons is maintained by efficient DNA
repair, while CNVs are more abundant in cancer-prone
individuals because of germline defects in these processes.
Although tumors are known to have increased somatic CNV
and instability, our model suggests these alterations arise
much earlier in cancer-predisposed individuals.
C CN NV Vs s   a an nd d   t tu um mo or r   g ge en no om me es s
So far we have focused here on CNVs and cancer predis-
position, but similar high-resolution approaches have also
driven recent studies on acquired (somatic) copy number
alterations (CNAs) in tumor DNA.
http://genomemedicine.com/content/1/6/62 Genome Medicine 2009, Volume 1, Issue 6, Article 62 Shlien and Malkin 62.5
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T Ta ab bl le e   1 1
R Ra ar re e   c ca an nc ce er r   C CN NV Vs s   a at t   k kn no ow wn n   c ca an nc ce er r- -p pr re ed di is sp po os si in ng g   g ge en ne es s
Gene Cancer syndrome References on genomic deletions or duplications
APC  Adenomatous polyposis coli; Turcot syndrome  Hodgson et al. [36], Su et al. [37], Aretz et al. [38] and 
Charames et al. [39]
BMPR1A  Juvenile polyposis  Delnatte et al. [40]
BRCA1  Hereditary breast/ovarian cancer  Petrij-Bosch et al. [41] and Montagna et al. [42]
BRCA2  Hereditary breast/ovarian cancer  Casilli et al. [43]
CDKN2A- p14ARF  Familial malignant melanoma  Lesueur et al. [44]
CDKN2A -p16(INK4a)  Familial malignant melanoma  Lesueur et al. [44]
CHEK2  Familial breast cancer  Cybulski et al. [45,46]
FANCA  Fanconi anemia A  Levran et al. [47]
MADH4  Juvenile polyposis  van Hattem et al. [48]
MEN1  Multiple endocrine neoplasia type 1  Kishi et al. [49]
MLH1  Hereditary non-polyposis colorectal cancer, Turcot syndrome  Nystrom-Lahti et al. [50] Chan et al. [51]
MSH2  Hereditary non-polyposis colorectal cancer  Stella et al. [52]
MSH6  Hereditary non-polyposis colorectal cancer  Plaschke et al. [53]
NF1  Neurofibromatosis type 1  Riva et al. [54], Bausch et al. [55]
NF2  Neurofibromatosis type 2  Tsilchorozidou et al. [56]
PRKAR1A  Carney complex  Horvath et al. [57]
PTCH  Nevoid basal cell carcinoma syndrome  Shimkets et al. [58]
RB1  Familial retinoblastoma  Bremner et al. [59]
SDHB  Familial paraganglioma  Cascon et al. [60]
SDHC  Familial paraganglioma  Baysal et al. [61]
SDHD  Familial paraganglioma  McWhinney et al. [62]
SMARCB1  Rhabdoid predisposition syndrome  Swensen et al. [63]
STK11  Peutz-Jeghers syndrome  Le Meur et al. [64]
TP53  Li-Fraumeni syndrome  Bougeard et al. [65,66]
TSC1  Tuberous sclerosis 1  Kozlowski et al. [67]
TSC2  Tuberous sclerosis 2  Kozlowski et al. [67]
VHL  von Hippel-Lindau syndrome  Richards et al. [68]
WT1  Denys-Drash syndrome, Frasier syndrome, Familial Wilms tumor  Huff et al. [69]
The 28 genes of the 70 germline cancer genes in the Cancer Genes Census [30] that have been reported to be mutated by genomic deletion or
duplication are shown. C Co op py y   n nu um mb be er r   a al lt te er ra at ti io on ns s
Genome-scale analyses have found many formerly invisible
CNAs. In an analysis of 371 lung adenocarcinoma samples
using a 250,000 probe array, Weir et al. [33] identified
seven recurrent homozygous deletions and 24 recurrent
amplifications. The most significant amplification, at
14q13.3 and containing the novel oncogene NKX2-1, had not
been found in previous studies; because of insufficient
resolution and sample size, the target gene it contained had
not been identified. Using an even denser array, Mullighan
et al. [34] profiled the DNA copy number changes of 242
pediatric acute lymphoblastic leukemia (ALL) patients,
including 192 with B-progenitor leukemia (B-ALL) and 50
with T-lineage leukemia (T-ALL). Global differences between
the subtypes’ genomes and recurrent abnormalities at
specific loci were identified. An average of six CNAs were
found per leukemia genome, but significant differences in
the number of CNAs were found within the B-ALL group and
between the B-ALL and T-ALL subtypes. Intriguingly, in
30% of B-ALL patients, the authors [34] detected deletions
of PAX5, a transcription factor that is expressed during early
stages of B-cell development. Using CNA analysis to
pinpoint critical genes can also help to plan subsequent
sequencing efforts. For example, having identified deletions
at  PAX5, the authors [34] found that an additional 14
patients had point mutations in the same gene.
U Us si in ng g   C CN NA As s   t to o   d de ef fi in ne e   t th he e   k ke ey y   p pa at th hw wa ay ys s   o of f   a a   t tu um mo or r
In glioblastoma, CNA information, mRNA expression levels
and methylation changes have been measured and nucleo-
tide mutational analyses have been carried out [35]. Inte-
grative analysis has shown that over 70% of tumors carry
alterations in the retinoblastoma, p53 and receptor tyrosine
kinase pathways. Although cancer is driven primarily by
alterations of the genome, this study [35] and others have
shown that CNA profiles can be combined with other high-
throughput data to create insights that are ‘greater than the
sum of their parts’.
C Co on nc cl lu us si io on ns s   a an nd d   p pe er rs sp pe ec ct ti iv ve es s
The study of cancer and CNVs is in its infancy but is
maturing quickly. In considering the effect of this form of
genetic variation on cancer predisposition, cancer gene
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F Fi ig gu ur re e   3 3
Proposed model for CNVs in tumorigenesis. A model of copy-number-variable DNA regions in patients with sporadic (top) or inherited (bottom)
cancer. We propose that healthy people maintain a similar low number of CNVs in their genomes (left; black blocks indicate inherited CNVs), whereas
those at risk of developing early onset cancer have an excess of CNVs and a greater overall genomic burden of copy-number-variable DNA (middle; red
blocks indicate somatically acquired CNVs). As a tumor grows, it acquires more copy-number-variable regions, including tumor-specific regions (blue).










































































regionsexpression and tumor genome profiling, there is much to
learn from past studies on genomic disorders. Denser micro-
arrays, next-generation sequencing and integrative infor-
matics analyses are around the corner and promise to
uncover new CNVs and CNAs.
There are, therefore, many exciting questions to be
addressed: what role do CNVs have in cancer predisposition
and how can we use this newly discovered form of genetic
variation to identify those most at risk? Which cancer-
related genes are affected by CNVs and, of these changes,
which are both necessary and sufficient to cause neoplastic
growth? Can incipient cancer cells use these constitutional
deletions and duplications to induce or accelerate
tumorigenesis and tumor proliferation? As these questions
are resolved, the potential value of cancer CNVs as novel bio-
markers of cancer susceptibility and initiation, and of cancer
progression and metastases, will become apparent. Whether
cancer CNVs offer insight into genes that might be targets
for novel drug development remains to be determined.
A Ab bb br re ev vi ia at ti io on ns s
CNA, copy number alteration; CNV, copy number variation;
DGV, Database of Genomic Variants; GWA, genome-wide
association; LFS, Li-Fraumeni syndrome; SMS, Smith-
Magenis syndrome; SNP, single nucleotide polymorphism.
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